Meeting
2017 Gastrointestinal Cancers Symposium
A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT).
Authors
Masato Nakamura
Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Japan
Masato Nakamura , Tae Won Kim , Rui-hua Xu , Young Suk Park , Yong Sang Hong , Tao Zhang , Takeshi Kato , Sang Hee Cho , Wei Wang , Hiroshi Matsuoka , Sae-Won Han , Yanhong Deng , Akitaka Makiyama , Keun-Wook Lee , Yi Ba , Mitsuyoshi Ota , Satoru Iwasa , Satoshi Morita , Yasuhide Yamada , Kei Muro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01996306. UMIN000012263.
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 681)
DOI
10.1200/JCO.2017.35.4_suppl.681
Abstract #
681
Poster Bd #
H11
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Differential association of proton pump inhibitors with efficacy of capecitabine and 5-fluorouracil in metastatic colorectal cancer: A post-hoc analysis from AXEPT phase III trial.
First Author: Sun Young Kim
Poster
2016 Gastrointestinal Cancers Symposium
A multinational, randomized, phase III trial of XELIRI (+bevacizumab) versus FOLFIRI (+bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).
First Author: Kei Muro
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando
Poster
2022 ASCO Annual Meeting
Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.
First Author: Zhichao Jiang